Review ArticleAARC Clinical Practice Guideline

Aerosol Delivery Device Selection for Spontaneously Breathing Patients: 2012

Arzu Ari and Ruben D Restrepo
Respiratory Care April 2012, 57 (4) 613-626; DOI: https://doi.org/10.4187/respcare.01756

References

  1. 1.↵
    1. Welch MJ
    . Nebulization therapy for asthma: a practical guide for the busy pediatrician. Clin Pediatr 2008;47(8):744–756.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Everard ML
    . Guidelines for devices and choices. J Aerosol Med 2001;14(Suppl 1):S59–S64.
    OpenUrl
  3. 3.↵
    National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma–summary report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94–S138. Erratum in: J Allergy Clin Immunol 2008;121(6):1330.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Devadason SG,
    2. Le Souef PN
    . Age-associated factors influencing the efficacy of various forms of aerosol therapy. J Aerosol Med 2002;15(3):343–345.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Pongracic JA
    . Asthma delivery devices: age-appropriate use. Pediatr Ann 2003;32(1):50–54.
    OpenUrlPubMed
  6. 6.↵
    1. Hess DR
    . Aerosol delivery devices in the treatment of asthma. Respir Care 2008;53(6):699–723.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Rau JL
    . Practical problems with aerosol therapy in COPD. Respir Care 2006;51(2):158–172.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Everard ML
    . Aerosol delivery to children. Pediatr Ann 2006;35(9):630–636.
    OpenUrlPubMed
  9. 9.↵
    1. Everard ML
    . Inhalation therapy for infants. Adv Drug Deliv Rev 2003;55(7):869–878.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Everard ML
    . Inhaler devices in infants and children: challenges and solutions. J Aerosol Med 2004;17(2):186–195.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Cole C
    . Special problems in aerosol delivery: neonatal and pediatric considerations. Respir Care 2000;45(6):646–651.
    OpenUrlPubMed
  12. 12.↵
    1. Brand P
    . Key issues in inhalation therapy in children. Curr Med Res Opin 2005;50(10):1313–1321.
    OpenUrl
  13. 13.↵
    1. Ahrens RC
    . The role of the MDI and DPI in pediatric patients: “children are not just miniature adults”. Respir Care 2005;50(10):1323–1328.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Ari A,
    2. Hess D,
    3. Myers TR,
    4. Rau JL
    . A guide to aerosol delivery devices for respiratory therapists 2nd ed. Irving, TX: American Association for Respiratory Care; 2009.
  15. 15.↵
    1. Rubin B,
    2. Fink J
    . Aerosol therapy for children. Respir Care Clin N Am 2001;7(2):100–108.
    OpenUrl
  16. 16.↵
    1. Lowenthal D,
    2. Kattan M
    . Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol 1992;14(3):192–196.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Erzinger S,
    2. Schueepp KG,
    3. Brooks-Wildhaber J,
    4. Devadason SG,
    5. Wildhaber JH
    . Facemasks and aerosol delivery in vivo. J Aerosol Med 2007;20(Suppl 1):S78–S83.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Nikander K,
    2. Berg E,
    3. Smaldone GC
    . Jet nebulizers versus pressurized metered dose inhalers with valved holding chambers: effects of the facemask on aerosol delivery. J Aerosol Med 2007;20(Suppl 1):S46–S55.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.
    1. Lin HL,
    2. Restrepo RD,
    3. Gardenhire DS,
    4. Rau JL
    . Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care 2007;52(8):1021–1026.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    1. Smaldone GC,
    2. Sangwan S,
    3. Shah A
    . Facemask design, facial deposition, and delivered dose of nebulized aerosols. J Aerosol Med 2007;20(Suppl 1):S66–S75.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Amirav I,
    2. Newhouse MT
    . Review of optimal characteristics of face-masks for valved-holding chambers (VHCs). Pediatr Pulmonol 2008;43(3):268–274.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Amirav I,
    2. Newhouse MT
    . Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 2001;108(2):389–394.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Smaldone GC,
    2. Berg E,
    3. Nikander K
    . Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med 2005;18(3):354–363.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Sangwan S,
    2. Gurses BK,
    3. Smaldone GC
    . Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004;37(5):447–452.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Dolovich MB,
    2. Ahrens RC,
    3. Hess DR,
    4. Anderson P,
    5. Dhand R,
    6. Rau JL,
    7. et al
    ; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127(1):335–371.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Geller DE
    . Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50(10):1313–1321.
    OpenUrlAbstract/FREE Full Text
  27. 27.
    1. Cates CJ,
    2. Rowe BH,
    3. Bara A
    . Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2002(2):CD000052.
  28. 28.
    1. Parkin P,
    2. Saunders N,
    3. Diamond S,
    4. Winders P,
    5. Macarthur C
    . Randomized trial spacer vs nebulizer for acute asthma. Arch Dis Child 1995;72(3):239–240.
    OpenUrlAbstract/FREE Full Text
  29. 29.
    1. Kerem E,
    2. Levison H,
    3. Schuh S,
    4. O'Brodovich H,
    5. Reisman J,
    6. Bentur L,
    7. Canny GJ
    . Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr 1993;123(2):313–317.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.
    1. Deerojanawong J,
    2. Manuvakorn W,
    3. Prapphal N,
    4. Harnruthakorn C,
    5. Sritippavawan S,
    6. Samransamruaikit R
    . Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs jet nebulizer in young children with wheezing. Pediatr Pulmonol 2005;39(5):466–472.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.
    1. Ploin D,
    2. Chapuis FR,
    3. Stamm D,
    4. Robert J,
    5. David L,
    6. Chatelain PG,
    7. et al
    . High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: a double-blind, randomized equivalence trial. Pediatrics 2000;106(2 Pt 1):311–317.
    OpenUrlAbstract/FREE Full Text
  32. 32.
    1. Vilarinho LC,
    2. Cardeal Mendes CM,
    3. de Freitas Souza LS
    . Metered-dose inhalers with home-made spacers versus nebulizers to treat moderate wheezing attacks in children. J Pediatr (Rio J) 2003;79(5):403–412.
    OpenUrlPubMed
  33. 33.
    1. Delgado A,
    2. Chou KJ,
    3. Silver EJ,
    4. Crain EF
    . Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med 2003;157(1):76–80.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.
    1. Bacharier LB,
    2. Boner A,
    3. Carlsen KH,
    4. Eigenmann PA,
    5. Frischer T,
    6. Götz M,
    7. et al
    ; European Pediatric Asthma Group. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008;63(1):5–34. Erratum in: Allergy 2008;63(5):630.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Voshaar T,
    2. App E,
    3. Berdel D,
    4. Buhl R,
    5. Fischer J,
    6. Gessler T,
    7. et al
    ; Arbeitsgruppe Aerosolmedizin der Deutschen Gessellschaft für Pneumologie. [Recommendations for the choice of inhalatory systems for drug prescription]. Pneumologie 2001;55(12):579–586. Article in German.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Chapman K,
    2. Voshaar T,
    3. Virchow JC
    . Inhaler choice in primary practice. Eur Respir Rev 2005;14(96):117–122.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Boe J,
    2. Dennis JH,
    3. O'Driscoll BR,
    4. Bauer TT,
    5. Carone M,
    6. Dautzenberg B,
    7. et al
    ; European Respiratory Society Task Force On the Use of Nebulizers. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001;18(1):228–242.
    OpenUrlFREE Full Text
  38. 38.
    1. Dolovich MB,
    2. Dhand R
    . Aerosol drug delivery: developments in device design and clinical use. Lancet 2010;377(9770):1032–1045.
    OpenUrlPubMed
  39. 39.↵
    1. Ari A,
    2. Fink JB
    . Guidelines to aerosol devices in infants, children and adults: which to choose, why and how to achieve effective aerosol therapy? Expert Rev Respir Med 2011;5(4):561–572.
    OpenUrlPubMed
  40. 40.↵
    1. Everard ML,
    2. Clark AR,
    3. Milner AD
    . Drug delivery from jet nebulisers. Arch Dis Child 1992;67(5):586–591.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Rau JL
    . Design principles of liquid nebulization devices currently in use. Respir Care 2002;47(11):1257–1275.
    OpenUrlPubMed
  42. 42.↵
    1. Le Brun PP,
    2. de Boer AH,
    3. Heijerman HG,
    4. Frijlink HW
    . A review of the technical aspects of drug nebulization. Pharm World Sci 2000;22(3):75–81.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Hess DR
    . Nebulizers: principles and performance. Respir Care 2000;45(6):609–622.
    OpenUrlPubMed
  44. 44.↵
    1. Kurosaka F,
    2. Nishio H
    . Comparison of the bronchodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma. Allergol Int 2009;58(4):529–535.
    OpenUrlPubMed
  45. 45.
    1. Dhand R
    . Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 2008;21(1):45–60.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Dhand R
    . Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47(12):1406–1416.
    OpenUrlPubMed
  47. 47.↵
    1. Dolovich MB,
    2. Killian D,
    3. Wolff RK,
    4. Obminski G,
    5. Newhouse MT
    . Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am Rev Respir Dis 1977;115(3):397–402.
    OpenUrlPubMedWeb of Science
  48. 48.↵
    1. Hess DR
    . The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J Aerosol Med 2007;20(Suppl 1):S85–S98.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.
    1. Pollack C,
    2. Fleisch K,
    3. Dowsey K
    . Treatment of acute bronchospasm with β-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Ann Emerg Med 1995;26(5):552–557.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.
    1. Nava S,
    2. Karakurt S,
    3. Rampulla C,
    4. Braschi A,
    5. Fanfulla F
    . Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study. Intensive Care Med 2001;27(10):1627–1635.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.
    1. Brandao DC,
    2. Lima VM,
    3. Filho VG,
    4. Silva TS,
    5. Campos TF,
    6. Dean E,
    7. de Andrade AD
    . Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma. J Asthma 2009;46(4):356–361.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Fauroux B,
    2. Itti E,
    3. Pigeot J,
    4. Isabey D,
    5. Meignan M,
    6. Ferry G,
    7. et al
    . Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. Am J Respir Crit Care Med 2000;162(6):2265–2271.
    OpenUrlPubMed
  53. 53.↵
    1. Chatmongkolchart S,
    2. Schettino G,
    3. Dillman C,
    4. Kacmarek R,
    5. Hess D
    . In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. Crit Care Med 2002;30(11):2515–2519.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Branconnier M,
    2. Hess D
    . Albuterol delivery during noninvasive ventilation. Respir Care 2005;50(12):1649–1653.
    OpenUrlPubMed
  55. 55.↵
    1. Abdelrahim ME,
    2. Plant P,
    3. Chrystyn H
    . In-vitro characterisation of the nebulised dose during non-invasive ventilation. J Pharm Pharmacol 2010;62(8):966–972.
    OpenUrlPubMed
  56. 56.↵
    1. Reychler G
    . Comparison of lung deposition in two types of nebulization: intrapulmonary percussive ventilation vs jet nebulization. Chest 2004;125:502.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Reychler G,
    2. Wallemacq P,
    3. Rodenstein DO,
    4. Cumps J,
    5. Leal T,
    6. Liistro G
    . Comparison of lung deposition of amikacin by intrapulmonary percussive ventilation and jet nebulization by urinary monitoring. J Aerosol Med 2006;19(2):199–207.
    OpenUrlPubMed
  58. 58.↵
    1. Berlinski A,
    2. Willis JR,
    3. Leisenring T
    . In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization. Respir Care 2010;55(12):1671–1679.
    OpenUrlPubMed
  59. 59.↵
    1. Kelly H,
    2. Keim K,
    3. McWilliams B
    . Comparison of two methods of delivering continuously nebulized albuterol. Ann Pharmacotherapy 2003;37(1):23–26.
    OpenUrlAbstract/FREE Full Text
  60. 60.
    1. Papo MC,
    2. Frank J,
    3. Thompson AE
    . A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993;21(10):1479–1486.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Khine H,
    2. Fuchs SM,
    3. Saville AL
    . Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med 1996;3(11):1019–1024.
    OpenUrlPubMedWeb of Science
  62. 62.↵
    1. Camargo CA Jr.,
    2. Spooner CH,
    3. Rowe BH
    . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003(4):CD001115.
  63. 63.↵
    1. McPeck M,
    2. Tandon R,
    3. Hughes K,
    4. Smaldone GC
    . Aerosol delivery during continuous nebulization. Chest 1997;111(5):1200–1205.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Newman S
    . Aerosol generators and delivery systems. Respir Care 1991;36(9):939–951.
    OpenUrlPubMed
  65. 65.↵
    1. Yilmaz O,
    2. Sogut A,
    3. Kose U,
    4. Sakinci O,
    5. Yuksel H
    . Influence of ambulatory inhaled treatment with different devices on the duration of acute asthma findings in children. J Asthma 2009;46(2):191–193.
    OpenUrlPubMed
  66. 66.↵
    1. Rubin BK,
    2. Fink JB
    . Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care 2005;50(9):1191–1200.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Wildhaber JH,
    2. Janssens HM,
    3. Pierart F,
    4. Dore ND,
    5. Devadason SG,
    6. LeSouëf PN
    . High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000;29(5):389–393.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Wildhaber JH,
    2. Devadason SG,
    3. Hayden MJ,
    4. James R,
    5. Dufty AP,
    6. Fox RA,
    7. et al
    . Electrostatic charge on a plastic spacer device influences the delivery of salbutamol Eur Respir J 1996;9(19):1943–1946.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Wildhaber JH,
    2. Devadason SG,
    3. Eber E,
    4. Hayden MJ,
    5. Everard ML,
    6. Summers QA,
    7. LeSouëf PN
    . Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996;51(10):985–988.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Price D,
    2. Thomas M,
    3. Mitchell G,
    4. Niziol C,
    5. Featherstone R
    . Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath actuated device. Respir Med 2003;97(1):12–19.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    1. Berger WE,
    2. Leflein JG,
    3. Geller DE,
    4. Parasuraman B,
    5. Miller CJ,
    6. O'Brien CD,
    7. O'Dowd L
    . The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Allergy Asthma Proc 2010;31(1):26–39.
    OpenUrlPubMed
  72. 72.↵
    1. Pedersen S,
    2. Hansen O,
    3. Fuglsang G
    . Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65(3):308–310.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Amirav I,
    2. Newhouse MT
    . To inhale or not to inhale: is that the question? A simple method of DPI instruction. J Pediatr 2010;156(2):339–339, e331.
    OpenUrlPubMed
  74. 74.↵
    1. Amirav I,
    2. Newhouse MT,
    3. Mansour Y
    . Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 2005;39(5):447–451.
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    1. Chavez A,
    2. McCracken A,
    3. Berlinski AB
    . Effect of face mask dead volume, respiratory rate and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol 2010;45(3):224–229.
    OpenUrlPubMed
  76. 76.↵
    1. Smaldone GC
    . Assessing new technologies: patient-device interactions and deposition. Respir Care 2005;50(9):1151–1160.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Janssens HM,
    2. Tiddens HA
    . Facemasks and aerosol delivery by metered dose inhaler-valved holding chamber in young children: a tight seal makes the difference. J Aerosol Med 2007;20(Suppl 1):S59–S63.
    OpenUrlPubMed
  78. 78.↵
    1. Esposito-Festen J,
    2. Ates B,
    3. van Vliet F,
    4. Hop W,
    5. Tiddens H
    . Aerosol delivery to young children by pMDI-spacer: is facemask design important? Pediatr Allergy Immunol 2005;16(4):348–353.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    1. Geller DE
    . Clinical side effects during aerosol therapy: cutaneous and ocular effects. J Aerosol Med 2007;20(Suppl 1):S100–S109.
    OpenUrlPubMed
  80. 80.↵
    1. Amirav I,
    2. Shakked T,
    3. Broday DM,
    4. Katoshevski D
    . Numerical investigation of aerosol deposition at the eyes when using a hood inhaler for infants–a 3D simulation. J Aerosol Med Pulm Drug Deliv 2008;(2):207–214.
  81. 81.↵
    1. Kugelman A,
    2. Amirav I,
    3. Mor F,
    4. Riskin A,
    5. Bader D
    . Hood versus mask nebulization in infants with evolving bronchopulmonary dysplasia in the neonatal intensive care unit. J Perinatol 2006;26(1):31–36.
    OpenUrlPubMed
  82. 82.↵
    1. Amirav I,
    2. Balanov I,
    3. Gorenberg M,
    4. Groshar D,
    5. Luder AS
    . Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears! Arch Dis Child 2003;88(8):719–723.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Amirav I,
    2. Oron A,
    3. Tal G,
    4. Cesar K,
    5. Ballin A,
    6. Houri S,
    7. et al
    . Aerosol delivery in respiratory syncytial virus bronchiolitis: hood or face mask? J Pediatr 2005;147(5):627–631.
    OpenUrlPubMed
  84. 84.↵
    1. Kacmarek RM,
    2. Hess DR
    . The interface between patient and aerosol generator. Respir Care 1991;36(9):952–976.
    OpenUrl
  85. 85.↵
    1. Rau JL
    . Delivery of aerosolized drugs to neonatal and pediatric patients. Respir Care 1991;36(6):514–542.
    OpenUrl
  86. 86.↵
    1. Pedersen S
    . Choice of inhalation therapy in pediatrics. Eur Respir Rev 1994;4:85–88.
    OpenUrl
  87. 87.↵
    1. Scalabrin D,
    2. Naspitz C
    . Efficacy and side effects of salbutamol in acute asthma in children: comparison of the oral route and two different nebulizer systems. J Asthma 1993;30(1):51–59.
    OpenUrlPubMed
  88. 88.↵
    1. Canny G,
    2. Levison H
    . Childhood asthma: a rational approach to treatment. Ann Allergy 1990;64(5):406–418.
    OpenUrlPubMed
  89. 89.↵
    1. LaForce C,
    2. Ellis E,
    3. Kordansky D,
    4. Cocchetto D,
    5. Sharp J
    . Use and acceptance of Ventolin Rotacaps and the Rotohaler in 1235 asthmatic patients. Clin Therapeutics 1993;15(2):321–329.
    OpenUrlPubMed
  90. 90.↵
    1. Atkins PJ
    . Dry powder inhalers: an overview. Respir Care 2005;50(10):1304–1312.
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    1. Lyttle B,
    2. Hollestelle A
    . Asthma: assessment and management in a pediatric hospital Can Fam Physician 1993;39:793–798.
    OpenUrlPubMed
  92. 92.↵
    1. Spier S,
    2. Drblik S,
    3. Lamarre A,
    4. Lapierre G,
    5. Marcotte J,
    6. Bourgeois M
    . A protocol for aerosol therapy in acute hospitalized asthmatics. J Asthma 1992;29(6):401–405.
    OpenUrlPubMed
  93. 93.↵
    1. Rubin BK,
    2. Fink JB
    . The delivery of inhaled medication to the young children. Pediatr Clin North Am 2003;50(3):717–731.
    OpenUrlCrossRefPubMed
  94. 94.↵
    1. Fink JB
    . Inhalers in asthma management: is demonstration the key to compliance? Respir Care 2005;50(5):598–600.
    OpenUrlFREE Full Text
  95. 95.↵
    1. Fink JB,
    2. Rubin BK
    . Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005;50(10):1360–1374.
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    1. Bendefy I
    . Home nebulisers in childhood asthma: survey of hospital supervised use. BMJ 1991;302(6786):1180–1181.
    OpenUrlAbstract/FREE Full Text
  97. 97.↵
    1. Flume PA,
    2. Mogayzel PJ Jr.,
    3. Robinson KA,
    4. Rosenblatt RL,
    5. Quittell L,
    6. Marshall BC
    . Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010;182(3):298–306.
    OpenUrlCrossRefPubMedWeb of Science
  98. 98.↵
    1. Wexler M,
    2. Rhame F,
    3. Blumental M,
    4. Cameron S,
    5. June B,
    6. Fish L
    . Transmission of gram-negative bacilli to asthmatic children via home nebulizers. Ann Allergy 1991;66(3):267–271.
    OpenUrlPubMed
  99. 99.
    1. Vassal S,
    2. Taamma R,
    3. Marty N,
    4. Sardet A,
    5. d'Athis P,
    6. Brémont F,
    7. et al
    . Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control 2000;28(5):347–351.
    OpenUrlCrossRefPubMedWeb of Science
  100. 100.↵
    1. Estivariz C,
    2. Bhatti L,
    3. Pati R,
    4. Jensen B,
    5. Arduino MJ,
    6. Jernigan D,
    7. et al
    . An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 2006;130(5):1346–1353.
    OpenUrlCrossRefPubMed
  101. 101.
    1. Hamill R,
    2. Georghiou P,
    3. Koza M,
    4. Goepfert P,
    5. Zenon G
    . Respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995;122(10):762–766.
    OpenUrlPubMedWeb of Science
  102. 102.↵
    1. Rau JL,
    2. Restrepo RD
    . Nebulized bronchodilator formulations: unit-dose or multi-dose? Respir Care 2003;48(10):926–939.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    1. Lemming C,
    2. Marciel J,
    3. O'Malley C,
    4. Hazle L
    ; Cystic Fibrosis Foundation. Stopping the spread of germs. http://www.cff.org/UploadedFiles/LivingWithCF/StayingHealthy/Germs/StoppingTheSpread/Stopping-the-Spread-of-Germs.pdf. Accessed February 1, 2012.
  104. 104.
    1. Rosenfeld M,
    2. Emerson J,
    3. Astley S,
    4. Joy P,
    5. Williams-Warren J,
    6. Standaert TA,
    7. et al
    . Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132(1):125–131.
    OpenUrlCrossRefPubMedWeb of Science
  105. 105.↵
    1. Hutchinson G,
    2. Parker S,
    3. Pryor J,
    4. Duncan-Skingle F,
    5. Hoffman P,
    6. Hodson M
    . Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996;34(3):584–587.
    OpenUrlAbstract/FREE Full Text
  106. 106.↵
    1. Segal-Maurer S,
    2. Kalkut G
    . Environmental control of tuberculosis: continuing controversy. Clin Infect Dis 1994;19(2):299–308.
    OpenUrlAbstract/FREE Full Text
  107. 107.↵
    1. Hui DS,
    2. Chow BK,
    3. Chu LC,
    4. Ng SS,
    5. Hall SD,
    6. Gin T,
    7. Chan MT
    . Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009;135(3):648–654.
    OpenUrlCrossRefPubMedWeb of Science
  108. 108.
    1. Simonds A,
    2. Hanak A,
    3. Chatwin M,
    4. Morrell M,
    5. Hall A,
    6. Parker K
    . Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebulizer treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborn infections. Health Technol Assess 2010;14(46):131–172.
    OpenUrlPubMed
  109. 109.↵
    1. Seitz T,
    2. Deitchman S
    . Health Hazard Evaluation Report: NIOSH Evaluation 1992;90–140. http://www.cdc.gov/niosh/hhe/reports/pdfs/1990-0140-2221.pdf. Accessed February 1, 2012.
  110. 110.↵
    1. Dimich-Ward H,
    2. Wymer ML,
    3. Chan-Yeung M
    . Respiratory health survey of respiratory therapists. Chest 2004;126(4):1048–1053.
    OpenUrlCrossRefPubMedWeb of Science
  111. 111.
    1. Carnathan B,
    2. Martin B,
    3. Colice G
    . Second hand (S)-albuterol: RT exposure risk following racemic albuterol (abstract). Respir Care 2001;46(10): 1084.
  112. 112.↵
    1. Christiani DC,
    2. Kern DG
    . Asthma risk and occupation as a respiratory therapist. Am Rev Respir Dis 1993;148(3):671–674.
    OpenUrlPubMedWeb of Science
  113. 113.↵
    1. Cochrane G,
    2. Bosley C
    . Compliance with inhaled therapy in asthma Eur Respir Rev 1994;4:92–94.
    OpenUrl
  114. 114.↵
    1. Guidry GG,
    2. Brown WD,
    3. Stogner SW,
    4. George RB
    . Incorrect use of metered dose inhalers by medical personnel. Chest 1992;101(1):31–33.
    OpenUrlCrossRefPubMedWeb of Science
  115. 115.↵
    1. Alvine GF,
    2. Rodgers P,
    3. Fitzsimmons KM,
    4. Ahrens RC
    . Disposable jet nebulizers. How reliable are they? Chest 1992;101(2):316–319.
    OpenUrlCrossRefPubMedWeb of Science
  116. 116.↵
    1. Merkus P,
    2. van Essen-Zandlilet E,
    3. Parievliet E,
    4. Borsboom G,
    5. Sterk P,
    6. Kerrebijn K
    . Changes of nebulizer output over the years. Eur Respir J 1992;5(4):488–491.
    OpenUrlAbstract/FREE Full Text
  117. 117.↵
    1. Snell N
    . Adverse reactions to inhaled drugs. Respir Med 1990;84(5):345–348.
    OpenUrlPubMed
  118. 118.
    1. Leuppi JD,
    2. Schnyder P,
    3. Hartmann K,
    4. Reinhart WH,
    5. Kuhn M
    . Drug-induced bronchospasm: analysis of 187 spontaneously reported cases. Respiration 2001;68(4):345–351.
    OpenUrlCrossRefPubMedWeb of Science
  119. 119.↵
    1. Babu KS,
    2. Marshall BG
    . Drug-induced airway diseases. Clin Chest Med 2004;25(1):113–122.
    OpenUrlCrossRefPubMedWeb of Science
  120. 120.↵
    1. Walia M,
    2. Paul L,
    3. Satyavani A,
    4. Lodha R,
    5. Kalaivani M,
    6. Kabra SK
    . Assessment of inhalation technique and determinants of incorrect performance among children with asthma. Pediatr Pulmonol 2006;41(11):1082–1087.
    OpenUrlCrossRefPubMedWeb of Science
  121. 121.↵
    1. Steckel H,
    2. Eskandar F
    . Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci 2003;19(5):443–455.
    OpenUrlPubMed
  122. 122.
    1. O'Callaghan C,
    2. Barry PW
    . The science of nebulised drug delivery. Thorax 1997;52(Suppl 2):S31–S44.
    OpenUrlCrossRefPubMedWeb of Science
  123. 123.↵
    1. Ip AY,
    2. Niven RW
    . Prediction and experimental determination of solute output from a Collison nebulizer. J Pharm Sci 1994;83(7):1047–1051.
    OpenUrlCrossRefPubMed
  124. 124.↵
    1. Tablan OC,
    2. Anderson LJ,
    3. Besser R,
    4. Bridges C,
    5. Hajjeh R
    . Guidelines for preventing health care–associated pneumonia 2003. Recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 2004;53(RR–3):1–36.
    OpenUrlPubMed
  125. 125.↵
    1. Sly R
    . Aerosol therapy in children. Respir Care 1991;36(9):994–1007.
    OpenUrl
  126. 126.↵
    1. Rau JL
    . The inhalation of drugs: advantages and problems. Respir Care 2005;50(3):367–382.
    OpenUrlAbstract/FREE Full Text
  127. 127.↵
    1. Rubin BK,
    2. Durotoye L
    . How do patients determine that their metered-dose inhaler is empty? Chest 2004;126(4):1134–1137.
    OpenUrlCrossRefPubMed
  128. 128.↵
    1. Berg E,
    2. Picard R
    . In-vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir Care 54(12):1671–1678, 2009.
    OpenUrlPubMed
  129. 129.↵
    1. Phipps P,
    2. Gonda I
    . Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 1990;97(6):1327–1332.
    OpenUrl
  130. 130.↵
    1. Dolovich M
    . Clinical aspects of aerosol physics. Respir Care 1991;36(9):931–938.
    OpenUrl
  131. 131.
    1. Mason J,
    2. Miller W,
    3. Small S
    . Comparison of aerosol delivery via Circulaire system vs conventional small volume nebulizer. Respir Care 1994;39(12):1157–1161.
    OpenUrl
  132. 132.
    1. Agnew J
    . Characterizing lung aerosol penetration. J Aerosol Med 1991;4:237–249.
    OpenUrl
  133. 133.↵
    1. Restrepo RD,
    2. Dickson SK,
    3. Rau JL,
    4. Gardenhire DS
    . An investigation of nebulized bronchodilator delivery using a pediatric lung model of spontaneous breathing. Respir Care 2006;51(1):56–61.
    OpenUrlAbstract/FREE Full Text
  134. 134.↵
    1. Hess D,
    2. Fisher D,
    3. Williams P,
    4. Pooler S,
    5. Kacmarek RM
    . Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110(2):498–505.
    OpenUrlCrossRefPubMedWeb of Science
  135. 135.↵
    1. Silverman M
    . Aerosol therapy in the newborn. Arch Dis Child 1990;65(8):906–908.
    OpenUrlFREE Full Text
  136. 136.↵
    1. Salmon B,
    2. Wilson N,
    3. Silverman M
    . How much aerosol reaches the lungs of wheezy infants and toddlers? Arch Dis Child 1990;65(4):410–413.
    OpenUrl
  137. 137.↵
    1. Iles R,
    2. Lister P,
    3. Edmunds AT
    . Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81(2):163–165.
    OpenUrlAbstract/FREE Full Text
  138. 138.↵
    1. Everard ML
    . Trying to deliver aerosols to upset children is a thankless task. Arch Dis Child 2000;82(5): 428.
  139. 139.↵
    1. Janssens HM,
    2. van der Wiel EC,
    3. Verbraak AF,
    4. de Jongste JC,
    5. Merkus PJ,
    6. Tiddens HA
    . Aerosol therapy and the fighting toddler: is administration during sleep an alternative? J Aerosol Med 2003;16(4):395–400.
    OpenUrlCrossRefPubMedWeb of Science
  140. 140.↵
    1. Bowton D,
    2. Goldsmith W,
    3. Haponik E
    . Substitution of metered-dose inhalers for hand-held nebulizers: success and cost savings in a large, acute-care hospital. Chest 1992;101(2):305–308.
    OpenUrlCrossRefPubMedWeb of Science
  141. 141.↵
    1. Tenholder M,
    2. Bryson M,
    3. Whitlock W
    . A model for conversion from small volume nebulizer to metered dose inhaler aerosol therapy. Chest 1992;101(3):634–637.
    OpenUrlCrossRefPubMedWeb of Science
  142. 142.↵
    1. Orens D,
    2. Kester L,
    3. Fergus L,
    4. Stoller J
    . Cost impact of metered dose inhalers vs small volume nebulizers in hospitalized patients: the Cleveland Clinic experience. Respir Care 1991;36(10):1099–1104.
    OpenUrlPubMed
  143. 143.↵
    1. Yuksel B,
    2. Greenough A,
    3. Maconochie I
    . Effective bronchodilator treatment by a simple spacer device for wheezy premature infants. Arch Dis Child 1990;65(7):782–785.
    OpenUrlAbstract/FREE Full Text
  144. 144.↵
    1. Osman L,
    2. Hyland M
    . Patient needs and medication styles in COPD. Eur Respir Rev 2005;14(96):89–92.
    OpenUrlAbstract/FREE Full Text
  145. 145.↵
    1. Zainudin B,
    2. Biddiscombe M,
    3. Tolfree S,
    4. Short M,
    5. Spiro S
    . Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990;45(6):469–473.
    OpenUrlAbstract/FREE Full Text
  146. 146.
    1. Wildhaber JH,
    2. Dore ND,
    3. Wilson JM,
    4. Devadason SG,
    5. LeSouëf PN
    . Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999;135(1):28–33.
    OpenUrlCrossRefPubMedWeb of Science
  147. 147.↵
    1. Fok T,
    2. Lam K,
    3. Ng P,
    4. Leung TF,
    5. So HK,
    6. Cheung KL,
    7. Wong W
    . Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Respir J 1998;12(1):159–164.
    OpenUrlAbstract
  148. 148.↵
    1. Mitchell JP,
    2. Nagel MW
    . Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J 2007;16(4):207–214.
    OpenUrlCrossRefPubMed
  149. 149.↵
    1. Janssens H,
    2. Heijnen E,
    3. de Jong V,
    4. Holland W,
    5. de Jongste J,
    6. Tiddens H
    . Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Repir J 2000;16(5):850–856.
    OpenUrl
  150. 150.
    1. Shah S,
    2. Berlinski A,
    3. Rubin BK
    . Force-dependent static dead space of face masks used with holding chambers Respir Care 2006;51(2):140–144.
    OpenUrlPubMedWeb of Science
  151. 151.
    1. Hayden J,
    2. Smith N,
    3. Woolf D,
    4. Barry P,
    5. O'Callaghan C
    . A randomised crossover trial of facemask efficacy. Arch Dis Child 2004;89(1):72–73.
    OpenUrlAbstract/FREE Full Text
  152. 152.
    1. Amirav I,
    2. Mansour Y,
    3. Mandelberg A,
    4. Bar-Ilan I,
    5. Newhouse M
    . Redesigned face mask improves “real life” aerosol delivery for Nebuchamber. Pediatr Pulmonol 2004;37(2):172–177.
    OpenUrlPubMedWeb of Science
  153. 153.
    1. Amirav I
    . Infant aerosol holding chamber face masks: not all are born equal! Respir Care 2006;51(2):123–125.
    OpenUrlPubMed
  154. 154.↵
    1. Janssens H,
    2. Tiddens H
    . Aerosol therapy: the special needs of young children. Pediatr Respir Rev 2006;7(Suppl 1):S83–S85.
    OpenUrl
  155. 155.↵
    1. Rubin BK
    . Bye-bye, blow-by (editorial). Respir Care 2007;52(8):981.
    OpenUrlFREE Full Text
  156. 156.↵
    1. Lin L,
    2. Restrepo RD,
    3. Gardenhire DS,
    4. Rau JL
    . Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care 2007;52(8):1021–1026.
    OpenUrlPubMedWeb of Science
  157. 157.↵
    1. Vidgren MT
    . Factors influencing lung deposition of inhaled aerosols. Eur Respir J 1994;4:68–70.
    OpenUrl
  158. 158.↵
    1. Kurosaka F,
    2. Nishio H
    . Comparison of the bronhodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma Allergol Int 2009;58(4):529–535.
    OpenUrlPubMed
  159. 159.↵
    1. Dhuper S,
    2. Chandra A,
    3. Ahmed A,
    4. Bista S,
    5. Moghekar A,
    6. Verma R,
    7. et al
    . Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma treatment. J Emerg Med 2011;40(3):247–255.
    OpenUrlPubMed
  160. 160.
    1. Leversha AM,
    2. Campanella SG,
    3. Aickin RP,
    4. Asher MI
    . Costs and effectiveness of spacer versus nebuliser in young children with moderate and severe acute asthma. J Pediatr 2000(4):497–502.
  161. 161.
    1. Turner MO,
    2. Gafni A,
    3. Swan D,
    4. FitzGerald JM
    . A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med 1996;156(18)2113–2118.
    OpenUrlCrossRefPubMedWeb of Science
  162. 162.
    1. Jasper A,
    2. Monhsenifar Z,
    3. Kahan S,
    4. Goldberg H,
    5. Koerner S
    . Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest 1987;91(4):614–618.
    OpenUrlCrossRefPubMedWeb of Science
  163. 163.
    1. Dhuper S,
    2. Chandra A,
    3. Ahmed A,
    4. Bista S,
    5. Moghekar A,
    6. Verma R
    . Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma in an inner-city adult population. Am J Health Syst Pharm 2008;62(10):1053–1061.
    OpenUrl
  164. 164.↵
    1. Summer W,
    2. Elston R,
    3. Tharpe L,
    4. Nelson S,
    5. Haponik EF
    . Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care. Arch Intern Med 1989;149(3):618–623.
    OpenUrl
  165. 165.↵
    1. Salyer JW,
    2. DiBlasi RM,
    3. Crotwell DN,
    4. Cowan CA,
    5. Carter ER
    . The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience. Respir Care 2008;53(3):338–345.
    OpenUrlAbstract/FREE Full Text
  166. 166.↵
    1. Hendeles L,
    2. Hatton RC,
    3. Coons TJ,
    4. Carlson L
    . Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber. Am J Health Syst Pharm 2005;62(10):1053–1061.
    OpenUrlAbstract/FREE Full Text
  167. 167.↵
    1. Kim SH,
    2. Kwak HJ,
    3. Kim TB,
    4. Chang YS,
    5. Jeong JW,
    6. Kim CW,
    7. et al
    . Inappropriate techniques used by internal medicine residents with three kinds of inhalers (a metered dose inhaler, Diskus, and Turbuhaler): changes after a single teaching session. J Asthma 2009;46(9):944–950.
    OpenUrlPubMed
  168. 168.
    1. Cunha AJ,
    2. Santos MA,
    3. Galvão MG,
    4. Ibiapina AA
    . Knowledge of pediatricians in Rio de Janeiro, Brazil about inhalation therapy in asthmatic children. Allergol Immunopathol (Madr) 2003;31(2):87–90.
    OpenUrlPubMed
  169. 169.
    1. Self TH,
    2. Arnold LB,
    3. Czosnowski LM,
    4. Swanson JM,
    5. Swanson H
    . Inadequate skill of healthcare professionals in using asthma inhalation devices. J Asthma 2007;44(8):593–598.
    OpenUrlCrossRefPubMed
  170. 170.
    1. Amirav I,
    2. Burg F
    . The need to educate health professionals about childhood asthma. Arch Pediatr Adolesc Med 1994;148(12):1339–1343.
    OpenUrlCrossRefPubMed
  171. 171.↵
    1. Benjaponpitak S,
    2. Kraisarin C,
    3. Direkwattanachai C,
    4. Sasisakunporn C
    . Incorrect use of metered dose inhaler by pediatric residents. J Med Assoc Thai 1996;79(2):122–126.
    OpenUrlPubMed
  172. 172.↵
    1. Melani AS
    . Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 2007;78(3):233–245.
    OpenUrlPubMed
  173. 173.↵
    1. Lewis RM,
    2. Fink JB
    . Promoting adherence to inhaled therapy: building partnerships through patient education. Respir Care Clin N Am 2001;7(2):277–301.
    OpenUrlPubMed
  174. 174.↵
    1. Akapo S,
    2. Gupta J,
    3. Martinez E,
    4. McCrea C,
    5. Ye L,
    6. Roach M
    . Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacother 2008;42(10):1416–1424.
    OpenUrlCrossRefPubMed
  175. 175.
    1. Kamin W,
    2. Schwabe A,
    3. Kramer I
    . Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006;5(4):205–213.
    OpenUrlCrossRefPubMedWeb of Science
  176. 176.↵
    1. Burchett D,
    2. Darko W,
    3. Zahra J,
    4. Noviasky J,
    5. Probst L,
    6. Smith A
    . Mixing and compatibility guide for commonly used aerosolized medications. Am J Health Syst Pharm 2010;67(3):227–230.
    OpenUrlAbstract/FREE Full Text
  177. 177.↵
    1. Hagmolen of ten Have W,
    2. van de Berg N,
    3. Bindels P,
    4. van Aalderen W,
    5. van der Palen J
    . Assessment of inhalation technique in children in general practice:increased risk of incorrect performance with new device. J Asthma 2008;45(1):67–71.
    OpenUrlCrossRefPubMedWeb of Science
  178. 178.↵
    1. Rubin BK
    . What does it mean when a patient says, “My asthma medication is not working”? Chest 2004;126(3):972–981.
    OpenUrlCrossRefPubMedWeb of Science
  179. 179.↵
    1. Deerojanawong J,
    2. Promsaka na Sakolnakorn V,
    3. Prapphal N,
    4. Hanrutakorn C,
    5. Sritippayawan S
    . Evaluation of metered-dose inhaler administration technique among asthmatic children and their caregivers in Thailand. Asian Pac J Allergy Immunol 2009;27(2-3):87–93.
    OpenUrlPubMed
  180. 180.
    1. Lavorini F,
    2. Levy ML,
    3. Dekhuijzen PN,
    4. Crompton GK
    . Inhaler choice and inhalation technique: key factors for asthma control. Prim Care Respir J 2009;18(4):241–242.
    OpenUrlPubMed
  181. 181.↵
    1. Lavorini F,
    2. Magnan A,
    3. Dubus JC,
    4. Voshaar T,
    5. Corbetta L,
    6. Broeders M,
    7. et al
    . Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102(4):593–604.
    OpenUrlCrossRefPubMedWeb of Science
  182. 182.↵
    1. Caldwell N
    . Nebulization in hospitals and home: standardizing the variables. Eur Respir Rev 1994;4:99–101.
    OpenUrl
  183. 183.
    1. Burgess S,
    2. Sly P,
    3. Devadason S
    . Providing feedback on adherence increases use of preventive medication by asthmatic children. J Asthma 2010;47(2):198–201.
    OpenUrlCrossRefPubMedWeb of Science
  184. 184.↵
    1. Brand PL,
    2. van der Baan-Slootweg OH,
    3. Heynens JW,
    4. de Vries TW,
    5. Versteegh FG,
    6. Vreuls RC,
    7. et al
    . Comparison of handling and acceptability of two spacer devices in young children with asthma. Acta Paediatr 2001;90(2):133–136.
    OpenUrlPubMed
  185. 185.↵
    1. O'Malley CA,
    2. VandenBranden SL,
    3. Zheng XT,
    4. Polito AM,
    5. McColley SA
    . A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respir Care 2007;52(3):258–262.
    OpenUrlAbstract/FREE Full Text
  186. 186.↵
    1. Saiman L,
    2. Siegel J
    . Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003;31(3):S6–S62.
    OpenUrlCrossRefWeb of Science
  187. 187.↵
    Centers for Disease Control and Prevention. Guideline for prevention of nosocomial pneumonia. Respir Care 1994;39(12):1191–1236.
    OpenUrlPubMed
  188. 188.↵
    US Food and Drug Administration. Public Health Advisory: Contamination of multi-dose bottles of albuterol sulfate solution for inhalation (0.5%). April 19, 2002. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm170883.htm. Accessed February 1, 2012.
  189. 189.↵
    1. Guyatt G,
    2. Oxman A,
    3. Vist Gea
    . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924–926.
    OpenUrlFREE Full Text
  190. 190.↵
    1. Jaeschke R,
    2. Guyatt G,
    3. Dellinger P,
    4. Schünemann H,
    5. Levy M,
    6. Kunz Rea
    . Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744. DOI:10.1136/bmj.a744.
    OpenUrlFREE Full Text
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords